Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice

Journal of Neuroimmunology

Volumn 211, Issue 1-2, 2009, Pages 92-100

  Thorne, Michael ^a   Moore, Craig S ^a   Robertson, George S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Darbepoetin alfa; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Tissue inhibitor of metalloprotease

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEMATOCRIT; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPINAL CORD; WILD TYPE;

ANIMALS; ASTROCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ERYTHROPOIETIN; FEMALE; HEMATINICS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPINAL CORD; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 67349181321     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.04.003     Document Type: Article

References (68)

1. Agnello D., Bigini P., Villa P., Mennini T., Cerami A., Brines M.L., and Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 952 (2002) 128-134
2. Ann M.R., and Rudick R.A. Drug insight: interferon treatment in multiple sclerosis. Nat. Clin. Pract. Neurol. 2 (2006) 34-44
3. Astier A.L. T-cell regulation by CD46 and its relevance in multiple sclerosis. Immunology 124 (2008) 149-154
4. Astier A.L., and Hafler D.A. Abnormal Tr1 differentiation in multiple sclerosis. J. Neuroimmunol. 191 (2007) 70-78
5. Astier A.L., Meiffren G., Freeman S., and Hafler D.A. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 116 (2006) 3252-3257
6. Benveniste E.N. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. 75 (1997) 165-173
7. Bermel R.A., and Rudick R.A. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics 4 (2007) 633-646
8. Boissy A., and Fox R.J. Current treatment options in multiple sclerosis. Curr. Treat. Options Neurol. 9 (2007) 176-186
9. Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., and Altunayoglu V. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin. Neurol. Neurosurg. 108 (2006) 124-128
10. Bruck W., and Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol. Sci. 24 Suppl 5 (2003) S265-S267
11. Carson K.R., Evens A.M., Bennett C.L., and Luminari S. Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best. Pract. Res. Clin. Haematol. 18 (2005) 467-472
12. Cases A. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Drugs Today (Barc.) 39 (2003) 477-495
13. Chan C.Y., Chen Y.S., Lee H.H., Huang H.S., Lai Y.L., Chen C.F., and Ma M.C. Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway. Life Sci. 81 (2007) 717-723
14. Chen G., Shi J.X., Hang C.H., Xie W., Liu J., and Liu X. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci. Lett. 425 (2007) 177-182
15. Chong Z.Z., Kang J.Q., and Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Cereb. Blood Flow Metab. 22 (2002) 503-514
16. Chopp M., Li Y., and Zhang J. Plasticity and remodeling of brain. J. Neurol. Sci. 265 (2008) 97-101
17. Clements J.M., Cossins J.A., Wells G.M., Corkill D.J., Helfrich K., Wood L.M., Pigott R., Stabler G., Ward G.A., Gearing A.J., and Miller K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 74 (1997) 85-94
18. Correale J., and Villa A. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting. Autoimmunity 40 (2007) 148-160
19. Crocker S.J., Whitmire J.K., Frausto R.F., Chertboonmuang P., Soloway P.D., Whitton J.L., and Campbell I.L. Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am. J. Pathol. 169 (2006) 2104-2116
20. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., and Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55 (1996) 1194-1204
21. Egrie J.C., Dwyer E., Browne J.K., Hitz A., and Lykos M.A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 31 (2003) 290-299
22. Ehrenreich H., Aust C., Krampe H., Jahn H., Jacob S., Herrmann M., and Siren A.L. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab. Brain Dis. 19 (2004) 195-206
23. Ehrenreich H., Fischer B., Norra C., Schellenberger F., Stender N., Stiefel M., Siren A.L., Paulus W., Nave K.A., Gold R., and Bartels C. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130 (2007) 2577-2588
24. Gijbels K., Galardy R.E., and Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest 94 (1994) 2177-2182
25. Gijbels K., Masure S., Carton H., and Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41 (1992) 29-34
26. Gold R., Hartung H.P., and Toyka K.V. Animal models for autoimmune demyelinating disorders of the nervous system. Mol. Med. Today 6 (2000) 88-91
27. Hasselblatt M., Ehrenreich H., and Siren A.L. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J. Neurosurg. Anesthesiol. 18 (2006) 132-138
28. Jelkmann W.E., Fandrey J., Frede S., and Pagel H. Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. Ann. N.Y. Acad. Sci. 718 (1994) 300-309
29. Jenkins T.M., Khaleeli Z., and Thompson A.J. Diagnosis and management of primary progressive multiple sclerosis. Minerva Med. 99 (2008) 141-155
30. Kadri Z., Petitfrere E., Boudot C., Freyssinier J.M., Fichelson S., Mayeux P., Emonard H., Hornebeck W., Haye B., and Billat C. Erythropoietin induction of tissue inhibitors of metalloproteinase-1 expression and secretion is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. Cell Growth Differ. 11 (2000) 573-580
31. Kadri Z., Maouche-Chretien L., Rooke H.M., Orkin S.H., Romeo P.H., Mayeux P., Leboulch P., and Chretien S. Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation. Mol. Cell. Biol. 25 (2005) 7412-7422
32. Keswani S.C., Buldanlioglu U., Fischer A., Reed N., Polley M., Liang H., Zhou C.H., Jack C., Leitz G.J., and Hoke A. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann. Neurol. 56 (2004) 815-826
33. Kieseier B.C., Kiefer R., Clements J.M., Miller K., Wells G.M., Schweitzer T., Gearing A.J., and Hartung H.P. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121 Pt 1 (1998) 159-166
34. Kilic E., Kilic U., Soliz J., Bassetti C.L., Gassmann M., and Hermann D.M. Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB J. 19 (2005) 2026-2028
35. Kuerten S., and Angelov D.N. Comparing the CNS morphology and immunobiology of different EAE models in C57BL/6 mice - a step towards understanding the complexity of multiple sclerosis. Ann. Anat. 190 (2008) 1-15
36. Le Page E., Leray E., Taurin G., Coustans M., Chaperon J., Morrissey S.P., and Edan G. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J. Neurol. Neurosurg. Psychiatry 79 (2008) 52-56
37. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., Miller K., and Serum gelatinase B. TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122 Pt 2 (1999) 191-197
38. Lee M.M., Yoon B.J., Osiewicz K., Preston M., Bundy B., van Heeckeren A.M., Werb Z., and Soloway P.D. Tissue inhibitor of metalloproteinase 1 regulates resistance to infection. Infect. Immun. 73 (2005) 661-665
39. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K.M., Hauser S.L., and Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121 Pt 12 (1998) 2327-2334
40. Li W., Maeda Y., Yuan R.R., Elkabes S., Cook S., and Dowling P. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann. Neurol. 56 (2004) 767-777
41. Liedtke W., Cannella B., Mazzaccaro R.J., Clements J.M., Miller K.M., Wucherpfennig K.W., Gearing A.J., and Raine C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44 (1998) 35-46
42. Macdougall I.C., and Cooper A.C. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur. J. Clin. Invest 35 Suppl 3 (2005) 32-35
43. Marie J.C., Astier A.L., Rivailler P., Rabourdin-Combe C., Wild T.F., and Horvat B. Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat. Immunol. 3 (2002) 659-666
44. McPherson R.J., and Juul S.E. Recent trends in erythropoietin-mediated neuroprotection. Int. J. Dev. Neurosci. 26 (2008) 103-111
45. Moore C.S., Hebb A.L., and Robertson G.S. Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes. J. Neuroimmunol. 193 (2008) 94-105
46. Nagai A., Nakagawa E., Choi H.B., Hatori K., Kobayashi S., and Kim S.U. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J. Neuropathol. Exp. Neurol. 60 (2001) 386-392
47. Okuda Y., Okuda M., and Bernard C.C. Gender does not influence the susceptibility of C57BL/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol. Lett. 81 (2002) 25-29
48. Oliver A.R., Lyon G.M., and Ruddle N.H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J. Immunol. 171 (2003) 462-468
49. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., and Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152 (1998) 729-741
50. Proost P., Van Damme J., and Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192 (1993) 1175-1181
51. Ratajczak J., Majka M., Kijowski J., Baj M., Pan Z.K., Marquez L.A., Janowska-Wieczorek A., Ratajczak M.Z., and Biological significance of M.A.P.K. AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br. J. Haematol. 115 (2001) 195-204
52. Rosenberg G.A., Dencoff J.E., Correa Jr. N., Reiners M., and Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46 (1996) 1626-1632
53. Rudick R.A. Contemporary immunomodulatory therapy for multiple sclerosis. J. Neuro-ophthalmol. 21 (2001) 284-291
54. Rudick R.A., and Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert. Rev. Neurother. 4 (2004) 571-580
55. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., Lublin F.D., Weinstock-Guttman B., Wynn D.R., Lynn F., Panzara M.A., and Sandrock A.W. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 911-923
56. Sattler M.B., Merkler D., Maier K., Stadelmann C., Ehrenreich H., Bahr M., and Diem R. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death. Differ. 11 Suppl 2 (2004) S181-S192
57. Savino C., Pedotti R., Baggi F., Ubiali F., Gallo B., Nava S., Bigini P., Barbera S., Fumagalli E., Mennini T., Vezzani A., Rizzi M., Coleman T., Cerami A., Brines M., Ghezzi P., and Bianchi R. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J. Neuroimmunol. 172 (2006) 27-37
58. Scott S.D. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 22 (2002) 160S-165S
59. Siren A.L., Radyushkin K., Boretius S., Kammer D., Riechers C.C., Natt O., Sargin D., Watanabe T., Sperling S., Michaelis T., Price J., Meyer B., Frahm J., and Ehrenreich H. Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain 129 (2006) 480-489
60. Skundric D.S. Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective. Curr.Neurovasc.Res. 2 (2005) 349-362
61. Sonobe Y., Jin S., Wang J., Kawanokuchi J., Takeuchi H., Mizuno T., and Suzumura A. Chronological changes of CD4(+) and CD8(+) T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. Tohoku J. Exp. Med. 213 (2007) 329-339
62. Sugawa M., Sakurai Y., Ishikawa-Ieda Y., Suzuki H., and Asou H. Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci. Res. 44 (2002) 391-403
63. Teesalu T., Hinkkanen A.E., and Vaheri A. Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am. J. Pathol. 159 (2001) 2227-2237
64. Yatsiv I., Grigoriadis N., Simeonidou C., Stahel P.F., Schmidt O.I., Alexandrovitch A.G., Tsenter J., and Shohami E. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 19 (2005) 1701-1703
65. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., and Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21 (1998) 75-80
66. Yong V.W., Zabad R.K., Agrawal S., Goncalves D.A., and Metz L.M. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J. Neurol. Sci. 259 (2007) 79-84
67. Yuan R., Maeda Y., Li W., Lu W., Cook S., and Dowling P. Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS.ONE 3 (2008) e1924
68. Zhang J., Li Y., Cui Y., Chen J., Lu M., Elias S.B., and Chopp M. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 1034 (2005) 34-39